Search Results - "Verusio, C."

Dihydropyrimidine dehydrogenase pharmacogenetics for predicting fluoropyrimidine-related toxicity in the randomised, phase III adjuvant TOSCA trial in high-risk colon cancer patients by Ruzzo, A, Graziano, F, Galli, Fabio, Galli, Francesca, Rulli, E, Lonardi, S, Ronzoni, M, Massidda, B, Zagonel, V, Pella, N, Mucciarini, C, Labianca, R, Ionta, M T, Bagaloni, I, Veltri, E, Sozzi, P, Barni, S, Ricci, V, Foltran, L, Nicolini, M, Biondi, E, Bramati, A, Turci, D, Lazzarelli, S, Verusio, C, Bergamo, F, Sobrero, A, Frontini, L, Menghi, M, Magnani, M

“…Background: Dihydropyrimidine dehydrogenase (DPD) catabolises ∼85% of the administered dose of fluoropyrimidines. Functional DPYD gene variants cause…”
Get full text

Metronomic chemotherapy with oral vinorelbine (mVNR) and capecitabine (mCAPE) in advanced HER2-negative breast cancer patients: is it a way to optimize disease control? Final results of the VICTOR-2 study by Cazzaniga, M. E., Cortesi, L., Ferzi, A., Scaltriti, L., Cicchiello, F., Ciccarese, M., Della Torre, S., Villa, F., Giordano, M., Verusio, C., Nicolini, M., Gambaro, A. R., Zanlorenzi, L., Biraghi, E., Legramandi, L., Rulli, E.

“…Purpose The VICTOR-1 study demonstrated that the all-oral metronomic combination of vinorelbine and capecitabine is highly active and well tolerated in hormone…”
Get full text

An open-label, randomized phase III study of early switch maintenance vs delayed second-line nivolumab in advanced stage squamous non-small cell lung cancer (NSCLC) patients after standard first-line platinum-based chemotherapy: EDEN trial by Gelsomino, F., Tiseo, M., Boni, L., Cavanna, L., Camerini, A., Chiari, R., Verusio, C., Tognetto, M., Ardizzoni, A.

Get full text

Cancer, emotions, and cinema: a preliminary study about the changes experienced by oncological patients by Sarno, L., Ratti, M.M., Soldi, E., Derevianko, A., Verusio, C.

Get full text

Secondary ROS1 mutations and lorlatinib sensitivity in crizotinib-refractory ROS1 positive NSCLC: Results of the prospective PFROST trial by Landi, L., Tiseo, M., Heukamp, L.C., Menon, R., Spitaleri, G., Cortinovis, D.L., Delmonte, A., Galetta, D., D’Arcangelo, M., D’Incà, F., Bertrand, M., Jóri, B., Zacher, A., Gridelli, C., Novello, S., Chiari, R., Verusio, C., Crinò, L., Cappuzzo, F.

Get full text

Evaluation OF psychological aspects of taking care cancer patients: a multicentre study on a sample of caregivers by Ratti, M.M., Bertin, F., Rossi, A., Portaluppi, A., Marconi, M., Sarno, L., Verusio, C.

Get full text

Patient relationship training in an integrated perspective: guidelines for psychological intervention by Verusio, C., Ratti, M.M., Bertin, F., Portaluppi, A., Rossi, A., Sarno, L., Marconi, M.

Get full text

Association between the development of autoimmune hypothyroidism and objective response to nivolumab: report of two cases by Di Lucca, G., Rossini, C., Morena, R., Banfi, L., Pogliani, C., Parati, M.C., Sali, L., Troisi, A., Verusio, C.

Get full text

Metronomic Chemotherapy in Triple-Negative Metastatic Breast Cancer: The Future Is Now? by Giordano, M., Verusio, C., Gambaro, A. R., Zanlorenzi, L., Biraghi, E., Casini, E., Legramandi, L., Rulli, E., Villa, F., Torre, S. Della, Ciccarese, M., Cicchiello, F., Scaltriti, L., Ferzi, A., Cortesi, Laura, Cazzaniga, M. E., Nicolini, Mario

“…Triple-negative breast cancer (TNBC) shows a very bad prognosis, even in early stages of disease. Metronomic chemotherapy refers to the minimum biologically…”
Get full text

Prospective dosimetry with 99mTc-MDP in metabolic radiotherapy of bone metastases with 153Sm-EDTMP by Bianchi, L., Baroli, A., Marzoli, L., Verusio, C., Chiesa, C., Pozzi, L.

“…Purpose On the basis of the encouraging results achieved in several clinical trials and its proven therapeutic efficacy, 153 Sm-ethylene diamine tetramethylene…”
Get full text

Cisplatin versus carboplatin in combination with mitomycin and vinblastine in advanced non small cell lung cancer. A multicenter, randomized phase III trial by Paccagnella, Adriano, Favaretto, A., Oniga, F., Barbieri, F., Ceresoli, G., Torri, W., Villa, E., Verusio, C., Cetto, G.L., Santo, A., De Pangher, V., Artioli, F., Cacciani, G.C., Parodi, G., Soresi, F., Ghi, M.G., Morabito, A., Biason, R., Giusto, M., Mosconi, P., Chiarion Sileni, V.

“…Background: In advanced not selected NSCLC chemotherapy achieved an advantage of approximately 1–2 months on median survival versus best supportive care…”
Get full text

PO-2277 Inter/intra-operator comparison study in daily CBCT for prostate IGRT with or without fiducials by De Cicco, L., Marzoli, L., Mancuso, R.M., Lorusso, R., Petazzi, E., Lanceni, A.G., Della Bosca, E., Buttignol, S., Starace, A., Bortolato, B., Verusio, C.

Get full text

186TiPAn open-label, randomized phase III study of early switch maintenance vs delayed second-line nivolumab in advanced stage squamous non-small cell lung cancer (NSCLC) patients after standard first-line platinum-based chemotherapy: EDEN trial by Gelsomino, F, Tiseo, M, Boni, L, Cavanna, L, Camerini, A, Chiari, R, Verusio, C, Tognetto, M, Ardizzoni, A

Get full text

Psychosocial distress and individuals needs: a HuCARE-based mediation moderation analysis in oncological population – a preliminary study by Rossi, A., Marconi, M., Guarnerio, C., Verusio, C.

Get full text

Psychosocial distress in project HuCARE - a preliminary study by Marconi, M., Rossi, A., Guarnerio, C., Verusio, C.

Get full text

Safety and efficacy of nivolumab for metastatic renal cell carcinoma: real‐world results from an expanded access programme by De Giorgi, Ugo, Cartenì, Giacomo, Giannarelli, Diana, Basso, Umberto, Galli, Luca, Cortesi, Enrico, Caserta, Claudia, Pignata, Sandro, Sabbatini, Roberto, Bearz, Alessandra, Buti, Sebastiano, Lo Re, Giovanni, Berruti, Alfredo, Bracarda, Sergio, Cognetti, Francesco, Rastelli, Francesca, Fornarini, Giuseppe, Porta, Camillo, Turci, Daniele, Sternberg, Cora N., Procopio, Giuseppe, Falcone, A., Roila, F., Cascinu, S., Tirelli, U., Giustini, L., Sobrero, A., Cappuzzo, F., Tassinari, D., Passalacqua, R., Pazzola, A., Surico, G., Maio, M., Benedetti, G., Barone, C., Adamo, V., Ricevuto, E., De Censi, A., Spada, M., Tonini, G., Pinto, C., Ciuffreda, L., Ruggeri, E. M., Bengala, C., Scotti, V., Fagnani, D., Bonetti, A., Mitterer, M., Castiglione, F., Bidoli, P., Ferraù, F., Crinò, L., Frassoldati, A., Marchetti, P., Mini, E., Scoppola, A., Verusio, C., Favaretto, A., Di Costanzo, F., Fasola, G., Merlano, M., Artioli, F., Di Leo, A., Romito, S., Maestri, A., Giannitto Giorgio, C., Ionta, M. T., Verderame, F., Zampa, G., Numico, G., Minelli, M., Tagliaferri, P., Foa, P., Palmiotti, G., De Placido, S., Mattioli, R., Iuliano, F., Defraia, E., Siena, S., Clerico, M., Salvagno, L., Ceresoli, G. L., Bernardo, A., Di Lieto, M., Moroni, M., Maisano, M., Scartozzi, M., Scagliotti, G., Sorarù, M., Pepe, S., Scaltriti, A., Gebbia, V., Testa, E., Lorusso, V., Bordonaro, R., De Signoribus, G., Tedde, N., Santoro, A., Francini, G., Aondio, G.

“…Objective To report the safety and efficacy results of patients enrolled in the Italian Nivolumab Renal Cell Cancer Expanded Access Programme. Patients and…”
Get full text

Use of dose-volume histograms and biophysical models to compare 2D and 3D irradiation techniques for non-small cell lung cancer by Ragazzi, G, Cattaneo, G M, Fiorino, C, Ceresoli, G, Verusio, C, Villa, E, Calandrino, R

“…For non-small cell lung cancer (NSCLC), unsatisfactory local control (LC) still remains an important cause of failure. It has been suggested that improved LC…”
Get full text

1489PD - Secondary ROS1 mutations and lorlatinib sensitivity in crizotinib-refractory ROS1 positive NSCLC: Results of the prospective PFROST trial by Landi, L., Tiseo, M., Heukamp, L.C., Menon, R., Spitaleri, G., Cortinovis, D.L., Delmonte, A., Galetta, D., D’Arcangelo, M., D’Incà, F., Bertrand, M., Jóri, B., Zacher, A., Gridelli, C., Novello, S., Chiari, R., Verusio, C., Crinò, L., Cappuzzo, F.

“…Lorlatinib, an ALK/ROS1 inhibitor, showed activity in ROS1+ NSCLC pretreated with crizotinib. However, molecular events predictive for tumor response during…”
Get full text

1489PDSecondary ROS1 mutations and lorlatinib sensitivity in crizotinib-refractory ROS1 positive NSCLC: Results of the prospective PFROST trial by Landi, L, Tiseo, M, Heukamp, L C, Menon, R, Spitaleri, G, Cortinovis, D L, Delmonte, A, Galetta, D, D’Arcangelo, M, D’Incà, F, Bertrand, M, Jóri, B, Zacher, A, Gridelli, C, Novello, S, Chiari, R, Verusio, C, Crinò, L, Cappuzzo, F

“…Abstract Background Lorlatinib, an ALK/ROS1 inhibitor, showed activity in ROS1+ NSCLC pretreated with crizotinib. However, molecular events predictive for…”
Get full text

Combined therapy for primary central nervous system lymphoma in immunocompetent patients by Ferreri, A.J.M., Reni, M., Bolognesi, A., Verusio, C., Villa, E.

“…A retrospective series of 13 immunocompetent patients with histological diagnosis of primary central nervous system lymphoma (PCNSL) is presented. The series…”
Get full text